An interesting stock that came up in some of our conversations today is Outlook Therapeutics, Inc. (NASDAQ:OTLK). At current price of $0.91, the shares have already added 0.05 points (5.8% higher) from its previous close of $0.86. Should you buy or avoid them? The stock sets an active trading volume day with a reported 189420 contracts so far this session. OTLK shares had a relatively better volume day versus average trading capacity of 902.07 thousand shares, but with a 12.14 million float and a -3.9% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for OTLK stock indicates that the average analyst price target is $7.38 per share. This means the stock has a potential increase of 710.99% from where the OTLK share price has been trading recently.
During the recent trading session for Outlook Therapeutics, Inc. (NASDAQ:OTLK), the company witnessed their stock rise $0.02 over a week and tumble down $-0.23 from the price 20 days ago. When compared to their established 52-week high of $10.96, the high they recorded in their recent session happens to be higher. Their established 52-week high was attained by the company on 02/14/19. The recent low of $0.52 stood for a -91.7% since 12/30/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of -0.88 is also allocated to the stock. Since the beta is less than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for Outlook Therapeutics, Inc., the two-week RSI stands at 50.18. This figure suggests that OTLK stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current OTLK readings is similarly very revealing as it has a stochastic reading of 55.34% at this stage. This figure means that OTLK share price today is being neutral.
Technical chart claims that Outlook Therapeutics, Inc. (OTLK) would settle between $0.89/share to $0.91/share level. However, if the stock price goes below the $0.85 mark, then the market for Outlook Therapeutics, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $0.83 for its downside target.
Analysts at Ladenburg Thalmann, assumed coverage of OTLK assigning Buy rating, according to their opinion released on September 11. Oppenheimer, analysts launched coverage of Outlook Therapeutics, Inc. (NASDAQ:OTLK) stock with a Outperform recommendation, according to their flash note issued to investors on May 16. Analysts at Ascendiant Capital Markets, made their first call for the equity with a Buy recommendation, according to a research note that dated back to April 22.
OTLK equity has an average rating of 2, with the figure leaning towards a bullish end. 4 analysts who tracked the company were contacted by Reuters. Amongst them, 0 rated the stock as a hold while the remaining 4 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 4 analysts rated Outlook Therapeutics, Inc. (NASDAQ:OTLK) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Outlook Therapeutics, Inc. (OTLK)’s current-quarter revenues are projected to climb by nearly -76.6% to hit $250000, based on current consensus estimate. The firm’s full-year revenues are expected to expand by over -79.3% from $8.15 million to a noteworthy $1.69 million. At the other end of the current quarter income statement, Outlook Therapeutics, Inc. is expected to see its adjusted earnings surge by roughly 91% to hit $-0.23 per share. For the fiscal year, OTLK’s earnings are projected to climb by roughly 15.3% to hit $-1.05 per share.